Literature DB >> 6528986

A radioenzymatic assay for plasma adenosine.

D C German, N M Kredich.   

Abstract

A method for analysis of plasma adenosine which combines the principles of radioisotope dilution and enzymatic catalysis is presented. Plasma from venous heparinized blood containing the adenosine deaminase inhibitor 2'-deoxycoformycin is mixed with a small amount of [3H]adenosine and extracted with perchloric acid. Using highly purified enzyme and [gamma-32P]GTP as the phosphate donor, the neutralized extract then serves as substrate for adenosine kinase, and the AMP product is purified by high-performance liquid chromatography. Adenosine concentrations in plasma are linearly proportional to 32P/3H ratios in the enzymatically synthesized AMP and are calculated from a standard curve. The advantages of the method are: ease of sample preparation; sensitivity of 20 nM in as little as 0.3 ml plasma; 20 samples per day can be analyzed by a single operator. Care must be used when obtaining plasma since cellular contamination will affect results. Using this assay, human plasma adenosine levels are 0.121 +/- 0.054 microM for males and 0.101 +/- 0.067 microM for females.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6528986     DOI: 10.1016/0003-2697(84)90503-7

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  4 in total

1.  Influences of variation in total energy intake and dietary composition on regulation of fat cell lipolysis in ideal-weight subjects.

Authors:  H Kather; E Wieland; A Scheurer; G Vogel; U Wildenberg; C Joost
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

2.  Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity.

Authors:  Andrey V Zavialov; Ake Engström
Journal:  Biochem J       Date:  2005-10-01       Impact factor: 3.857

3.  Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.

Authors:  G A Rongen; P Smits; K Ver Donck; J J Willemsen; R A De Abreu; H Van Belle; T Thien
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

4.  Biochemical characterization of adenosine deaminase (CD26; EC 3.5.4.4) activity in human lymphocyte-rich peripheral blood mononuclear cells.

Authors:  L R Costa; A K Y de Souza; J N Scholl; F Figueiró; A M O Battastini; J A Dos Santos Jaques; F F Zanoelo
Journal:  Braz J Med Biol Res       Date:  2021-05-24       Impact factor: 2.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.